Approved indications: Truqap is approved, together with fulvestrant, for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors have at least one PIK3CA, AKT1, or PTEN alteration, after the cancer has progressed on at least one endocrine-based regimen in the metastatic setting or recurred within 12 months of completing adjuvant endocrine therapy.

Off-label or investigational uses: Capivasertib (the active ingredient in Truqap) is being studied, mainly within clinical trials, for other cancers such as triple-negative breast cancer and advanced prostate cancers (castration-resistant or hormone-sensitive); these uses are not FDA-approved, and evidence is still emerging, so routine off-label use outside trials is limited.

Efficacy expectations: In the main CAPItello-291 trial of patients whose tumors had PIK3CA/AKT1/PTEN alterations, adding Truqap to fulvestrant roughly doubled median progression-free survival (about 7.3 vs 3.1 months) and led to tumor shrinkage in about one quarter of patients with measurable disease, with benefits typically becoming evident over weeks to a few months.

Comparison to similar drugs: Truqap provides an additional targeted option after endocrine-based therapy has failed in HR-positive, HER2-negative metastatic breast cancer with specific pathway alterations; its disease-control benefits are comparable to other targeted agents in this setting but with a distinct side-effect pattern dominated by diarrhea, skin reactions, and high blood sugar that requires proactive monitoring and management.

Standard adult dosing: The usual dose of Truqap is 400 mg by mouth twice daily (about 12 hours apart) for 4 consecutive days followed by 3 days off each week, taken with or without food and always in combination with fulvestrant injections.

How to take it: Swallow Truqap tablets whole with water without chewing, crushing, or splitting them, take the morning and evening doses at roughly the same times each treatment day, and do not use tablets that are broken, cracked, or look damaged; treatment generally continues as long as the cancer is controlled and side effects remain manageable.

Dose adjustments and special instructions: Your care team may reduce the dose (for example to 320 mg or 200 mg twice daily on the same 4-days-on/3-days-off schedule) or temporarily hold treatment if you have significant side effects or need certain interacting medicines, and premenopausal women and many men will also receive a luteinizing hormone-releasing hormone (LHRH) agonist along with fulvestrant.

Missed or vomited doses: If you miss a dose, you may still take it within 4 hours of the usual time; if more than 4 hours have passed, skip that dose and take the next one at the regular time, and if you vomit after taking a dose you should not take an extra tablet but wait until the next scheduled dose.

Overdose: If more tablets are taken than prescribed, contact your oncology team, local poison control center, or emergency medical services right away, and bring the medication container so healthcare providers know exactly what was taken.

Common side effects: The most frequent side effects include diarrhea, skin rashes or other cutaneous reactions, nausea, fatigue, vomiting, mouth sores, and laboratory changes such as high blood sugar, changes in blood cell counts, increased triglycerides, and mild increases in kidney or liver tests; these often start in the first few weeks and are usually mild to moderate but can become severe if not treated early.

• Serious problems needing urgent medical attention: very high blood sugar or diabetic ketoacidosis (extreme thirst, frequent urination, nausea, vomiting, abdominal pain, confusion, trouble breathing, fruity breath, or unusual sleepiness); severe diarrhea with signs of dehydration (dizziness, fainting, very little urine); severe skin reactions (rapidly worsening rash, blistering or peeling skin, sores in the mouth, eyes, or genitals, fever); signs of serious infection; symptoms of allergic reaction (facial or tongue swelling, trouble breathing, hives); or symptoms of kidney injury (swelling, decreased urination).

Warnings and precautions: Truqap commonly raises blood sugar and can cause severe hyperglycemia and rarely diabetic ketoacidosis, so fasting glucose and HbA1c must be checked before starting and regularly during treatment, and people with diabetes often need closer monitoring or medication adjustments; diarrhea and cutaneous reactions are also common and can be serious, sometimes requiring treatment breaks, dose reductions, or permanent discontinuation.

Pregnancy, breastfeeding, and age-related considerations: Truqap can harm an unborn baby and should not be used during pregnancy; effective contraception is required during treatment and for a period after the last dose for both females and males with partners who can become pregnant, and breastfeeding is not recommended while taking the drug; its safety and effectiveness are not established in children, and older adults may experience more severe side effects and need closer monitoring.

Overall safety profile: Compared with other targeted therapies for advanced HR-positive, HER2-negative breast cancer, Truqap has similar overall rates of moderate to severe side effects but a particularly high incidence of diarrhea, rash, and hyperglycemia, which can often be managed with early symptom reporting, supportive medicines (such as antidiarrheals and skin treatments), and dose adjustments.

Reporting side effects and safety updates: Patients and caregivers can report suspected side effects to the FDA at 1-800-FDA-1088 or through the online MedWatch system, and up-to-date safety information is available from the FDA and from the manufacturer in addition to guidance from the oncology care team.

Key prescription drug interactions: Strong or moderate CYP3A inhibitors (for example some azole antifungals, macrolide antibiotics, and certain HIV or hepatitis C treatments) can increase capivasertib levels and raise the risk of side effects, while strong or moderate CYP3A inducers (such as rifampin, carbamazepine, phenytoin, and St. John’s wort) can lower levels and reduce effectiveness, so these are generally avoided or require Truqap dose adjustments; Truqap itself can increase blood levels of some medicines metabolized by CYP3A, CYP2D6, or UGT1A1, so doses of sensitive drugs like certain sedatives, antidepressants, beta-blockers, and other narrow-therapeutic-index agents may need review.

OTC medicines and supplements: Over-the-counter drugs, vitamins, and herbal products should be reviewed with the oncology team, especially products that can affect liver enzymes (such as St. John’s wort) or blood sugar, or that increase bleeding risk when combined with other therapies.

Food, beverages, and alcohol: Truqap can be taken with or without food, but grapefruit and grapefruit juice should be avoided because they can increase drug levels; alcohol is not strictly contraindicated but may worsen side effects such as nausea, dehydration, or changes in blood sugar, so it should be limited or avoided based on individualized medical advice.

Medical conditions and co-medications requiring caution: Careful use and monitoring are needed in people with diabetes or prediabetes, moderate liver impairment, or reduced kidney function, and Truqap should not be used in anyone with a history of severe hypersensitivity to capivasertib; treatment is only appropriate when an approved test confirms a PIK3CA, AKT1, or PTEN alteration in the tumor and when it can be safely combined with fulvestrant and, when indicated, an LHRH agonist.

Monitoring needs: Before and during therapy, clinicians check fasting blood glucose and HbA1c regularly, and typically follow complete blood counts, kidney and liver function tests, and lipid levels, adding other tests such as ECGs or imaging scans when clinically indicated to monitor both safety and cancer response.

Q: What is Truqap and who is it for?
A: Truqap is an oral targeted cancer medicine (an AKT inhibitor) used with fulvestrant to treat adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors have specific gene changes in PIK3CA, AKT1, or PTEN after endocrine-based therapy has stopped working.

Q: Is Truqap a form of chemotherapy?
A: Truqap is not traditional chemotherapy; it is a targeted therapy that blocks a signaling protein (AKT) in cancer cells, but like chemotherapy it can still cause significant side effects and requires close monitoring.

Q: How soon might I see results from Truqap?
A: In clinical studies, many patients who benefited had disease control or tumor shrinkage seen on scans within the first few months, though the exact timing varies and your oncology team will schedule regular imaging and blood tests to assess response.

Q: Can I take Truqap if I have diabetes?
A: Some people with well-controlled type 2 diabetes can take Truqap, but the medicine often raises blood sugar and can occasionally cause severe hyperglycemia, so your blood glucose and HbA1c will be monitored closely and diabetes medicines may need adjustment; people with type 1 diabetes or insulin-dependent diabetes require very careful specialist oversight.

Q: What should I do if I miss a dose of Truqap?
A: If you realize within 4 hours of the usual time, you can take the missed dose; if more than 4 hours have passed, skip it and take your next dose at the regular time, and never double up to make up for a missed tablet.

Q: Will I need to stay on Truqap forever?
A: Treatment is generally continued as long as the cancer is controlled and side effects remain tolerable, and your oncology team will periodically review scan results, symptoms, and lab tests to decide whether to continue, adjust, or switch therapies.

Storage: Store Truqap tablets in the original child-resistant packaging at room temperature (68°F to 77°F / 20°C to 25°C), protect from excess heat and moisture, keep out of the reach of children, and if tablets are dispensed into another tight container keep them at room temperature and discard any unused tablets from that container after 45 days.

Disposal: Do not save unused or expired Truqap; use a pharmacy or community medicine take-back program when available, or ask your pharmacist or oncology team how to dispose of tablets safely, and do not flush them down the toilet unless you are specifically instructed to do so.